iguratimod has been researched along with Sclerosis, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gan, H; Li, F; Li, S; Liao, J; Tian, J; Wang, J; Xie, X | 1 |
| Bao, C; Cao, S; Chen, X; Fan, C; Fu, Q; Jin, Y; Lu, L; Shen, L; Sun, L; Xu, X; Yan, Q; Yin, H; Zhan, Y; Zhang, Z | 1 |
2 other study(ies) available for iguratimod and Sclerosis, Systemic
| Article | Year |
|---|---|
Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis.
Topics: Animals; Bleomycin; Chromones; Fibroblasts; Fibrosis; Mice; Scleroderma, Systemic; Signal Transduction; Skin; Smad Proteins; Sulfonamides; Transforming Growth Factor beta1 | 2022 |
Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression.
Topics: Animals; Antirheumatic Agents; Bleomycin; Chromones; Early Growth Response Protein 1; Fibrosis; Humans; Mice; Scleroderma, Systemic | 2023 |